What are the specifications of Nirapali, abiraterone tablets?

Niraparib tablets (Akeega) are a fixed compound preparation used to treat castration-resistant prostate cancer in specific groups. It is composed of two active ingredients: Niraparib, a PARP inhibitor, and Abiraterone acetate, an androgen synthesis inhibitor. Its specifications are designed to optimize the combined effects of drugs, while improving patients' medication compliance and reducing their medication burden.

Currently, there are two most common specifications of niraparib and abiraterone tablets in the global market: (500mg/50mg)*60 tablets and (500mg/100mg)*60 tablets. Here “500mg” represents the dose of abiraterone, while “50mg” or “100mg” corresponds to the dose of niraparib. This composite specification design provides flexible treatment options. Doctors can customize the appropriate dose of niraparib according to the patient's weight, tolerance and genetic background, thereby achieving precise treatment.

Generally, for patients whose body weight is ≥77kg or whose platelet count is ≥150,000/μL, the recommended daily dose is niraparib 200mg and abiraterone 1000mg, that is, two tablets (500mg/100mg). For patients who are underweight or have low platelets, a version containing 50 mg of niraparib may be considered. All specifications are designed to be taken once a day. Patients should follow the principle of oral administration on an empty stomach to avoid food affecting the bioavailability of the drug.

In terms of packaging, a bottle or box usually contains60 tablets, which are used to match the once-daily dosing strategy and are enough for one month. The packaging design clearly indicates the ingredients, batch number and expiration date to facilitate long-term and standardized use by patients. All specifications are produced by authoritative international pharmaceutical companies in accordance with GMP standards, and the stability and consistency of the drugs have been strictly verified.

At present, niraparibabiraterone tablets have not fully entered the Chinese market, so the availability of domestic specifications may be restricted and are mainly obtained through import channels or overseas medical treatment. Before it is officially introduced and included in medical insurance, patients need to rely on doctors to make personalized dosage selections and pay attention to specification matching and drug supply.

Reference materials:https://www.drugs.com/akeega.html